Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
Holding TEVA?
Track your performance easily
TEVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.06 - $19.08
Previous Close$18.07
Volume4.81M
Average Volume (3M)8.82M
Market Cap
$20.39B
Enterprise Value$37.26B
Total Cash (Recent Filing)$2.26B
Total Debt (Recent Filing)$18.92B
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 07, 2024EPS Estimate
$0.66Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding1,132,908,864
10 Day Avg. Volume8,318,527
30 Day Avg. Volume8,815,656
Standard Deviation0.11
R-Squared0.16
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.04
Price to Sales (P/S)1.28
Price to Cash Flow (P/CF)50.60
P/FCF Ratio869.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit4.87
Enterprise Value/Ebitda15.42
Forecast
1Y Price Target
$22.00Price Target Upside21.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Teva Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAustedo was a notable beat/raise and recent performance leads to increased near-term estimates.
Innovative PipelineOlanzapine LAI completes Phase 3 dosing with no PDSS, which could lead to approval and a significant revenue opportunity.
Product LaunchesTeva has recently launched a range of new drugs, including an extended release version of its treatment for tardive dyskinesia and Huntington's disease chorea, as well as generic versions of the blockbuster drug Humira, plaque psoriasis and psoriatic arthritis drug Stelara, and GLP-1 treatment for type 2 diabetes, Victoza.
Bears Say
Business PerformanceEx-gRevlimid, Teva’s North America generic business has underperformed expectations.
Legislation ImpactAustedo could be subject to drug price negotiations under IRA legislation, potentially impacting revenue in 2027 or 2028.
Market ExpectationsThere are higher expectations across Teva’s business, especially for the TL1A program and biosimilars, despite challenging market fundamentals.
---
Ownership Overview
0.65% Insiders
17.47% Mutual Funds
34.85% Other Institutional Investors
47.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $8.05 and its highest was $19.08 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Currently, no data Available
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jul 31, 2024. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.552 by $0.058.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is $0.66.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,132,992,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.61 in its last earnings report, beating expectations of $0.552. Following the earnings report the stock price went up 6.216%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 328M.
---
Teva Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (21.75% Upside)
$22.00 (21.75% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.21%
12-Months-Change
Fundamentals
Return on Equity
-6.61%
Trailing 12-Months
Asset Growth
-4.08%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEVA Company Deck
---
TEVA Earnings Call
Q2 2024
0:00 / 0:00
---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$22.00
▲(21.75% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+32.11%
reiterated a buy rating 2 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +32.11% per trade.
---